Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A New Quinoline BRD4 Inhibitor Targets a Distinct Latent HIV-1 Reservoir for Reactivation from Other “Shock” Drugs

17 Jan 2018

Abstract excerpt

ABSTRACT Upon HIV-1 infection, a reservoir of latently infected resting T cells prevents the eradication of the virus from patients. To achieve complete depletion, the existing virus-suppressing antiretroviral therapy must be combined with drugs that reactivate the dormant viruses. We previously described a novel chemical scaffold compound, MMQO (8-methoxy-6-methylquinolin-4-ol), that is able to reactivate viral...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to HIV/AIDS drug development and treatment
Share to HIV Research and Treatment
Share to Protein Degradation and Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 29343578
DOI: 10.1128/jvi.02056-17

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A New Quinoline BRD4 Inhibitor Targets a Distinct Latent HIV-1 Reservoir for Reactivation from Other “Shock” DrugsPMID 29343578Read ↗

BET bromodomain inhibition as a novel strategy for reactivation of HIV-1Semantic proximity Read ↗

Are BET Inhibitors yet Promising Latency-Reversing Agents for HIV-1 Reactivation in AIDS Therapy?Semantic proximity Read ↗

Mechanistic insights and <i>in vivo</i> HIV suppression by the BRD4-targeting small molecule ZL0580Semantic proximity Read ↗

BI-2536 and BI-6727, dual Polo-like kinase/bromodomain inhibitors, effectively reactivate latent HIV-1Semantic proximity Read ↗

Modulation of BRD4 in HIV epigenetic regulation: implications for finding an HIV cureSemantic proximity Read ↗

The BET bromodomain inhibitor JQ1 activates HIV latency through antagonizing Brd4 inhibition of Tat-transactivationSemantic proximity Read ↗

KDM5A/B contribute to HIV-1 latent infection and survival of HIV-1 infected cellsSemantic proximity Read ↗

Reactivation of Latent HIV-1 by Inhibition of BRD4Semantic proximity Read ↗

Inhibition of the TRIM24 bromodomain reactivates latent HIV-1Semantic proximity Read ↗

KDM5A/B promotes HIV-1 latency and KDM5 inhibitors promote HIV-1 lytic reactivationSemantic proximity Read ↗

An In-Depth Comparison of Latency-Reversing Agent Combinations in Various In Vitro and Ex Vivo HIV-1 Latency Models Identified Bryostatin-1+JQ1 and Ingenol-B+JQ1 to Potently Reactivate Viral Gene ExpressionSemantic proximity Read ↗

Inhibition of the TRIM24 bromodomain reactivates latent HIV-1Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.